Invasive procedures in patients undergoing treatment with lenvatinib for thyroid cancer

Lenvatinib is a multi-tyrosine kinase inhibitor that inhibits angiogenesis and is currently in use for the treatment of refractory thyroid cancer. Therapy using this agent can be prolonged in patients, although serious complications may ensue among those who require surgical procedures. To the best...

Descripción completa

Detalles Bibliográficos
Autores principales: Toda, Soji, Iwasaki, Hiroyuki, Murayama, Daisuke, Nakayama, Hirotaka, Suganuma, Nobuyasu, Masudo, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947953/
https://www.ncbi.nlm.nih.gov/pubmed/33758662
http://dx.doi.org/10.3892/mco.2021.2243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947953/
https://www.ncbi.nlm.nih.gov/pubmed/33758662
http://dx.doi.org/10.3892/mco.2021.2243

Ejemplares similares